Perflutren
As of the edition of 20 October 2026, Perflutren is a small molecule: marketed, first approved in 1998 (EU); US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2001
- Kind
- Small molecule
- Brand name
- Definity
- First approved
- 17 May 1998 (EU)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Lantheus Medical Imaging; 3 holders in all
- Registered trials
- 96, 14 stopped early
- Disease areas
- Cancer; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Digestive system
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by Lantheus Medical Imaging.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 26 | 15 | 5 | 4 |
| Phase 1 | 23 | 10 | 8 | 4 |
| Phase 2 | 21 | 12 | 3 | 5 |
| Phase 3 | 11 | 7 | 4 | 0 |
| Phase 4 | 15 | 13 | 1 | 1 |
| All trials | 96 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GE Healthcare | Applicant | 1998 to now |
| Lantheus Medical Imaging | Acquired holder and Lead sponsor of trials | 2004 to now |
| Lantheus | Later holder | 2006 to now |